|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-1-31
|
|
pubmed:abstractText |
Human epidermal growth factor receptor 2 (HER2) overexpression was found to predict a good response in breast carcinoma patients treated with doxorubicin (Adriamycin [ADM]). Evidence from our recent study indicates that node-positive patients respond to cyclophosphamide, methotrexate, and fluorouracil (CMF) regardless of HER2 status. We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BalsariAndreaA,
pubmed-author:BiganzoliEliaE,
pubmed-author:BonadonnaGianniG,
pubmed-author:BoracchiPatriziaP,
pubmed-author:CasaliniPatriziaP,
pubmed-author:MénardSylvieS,
pubmed-author:MarubiniEttoreE,
pubmed-author:MoliterniAngelaA,
pubmed-author:PilottiSilvanaS,
pubmed-author:TomasicGoranaG,
pubmed-author:ValagussaPinucciaP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
458-62
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12560435-Adult,
pubmed-meshheading:12560435-Aged,
pubmed-meshheading:12560435-Antineoplastic Agents,
pubmed-meshheading:12560435-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12560435-Breast Neoplasms,
pubmed-meshheading:12560435-Chemotherapy, Adjuvant,
pubmed-meshheading:12560435-Cyclophosphamide,
pubmed-meshheading:12560435-Doxorubicin,
pubmed-meshheading:12560435-Female,
pubmed-meshheading:12560435-Fluorouracil,
pubmed-meshheading:12560435-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12560435-Humans,
pubmed-meshheading:12560435-Immunohistochemistry,
pubmed-meshheading:12560435-Methotrexate,
pubmed-meshheading:12560435-Middle Aged,
pubmed-meshheading:12560435-Predictive Value of Tests,
pubmed-meshheading:12560435-Prognosis,
pubmed-meshheading:12560435-Receptor, erbB-2,
pubmed-meshheading:12560435-Survival
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
|
|
pubmed:affiliation |
Medical Oncology Unit, Department of Experimental Oncology, Scientific Direction, Istituto Nazionale Tumori, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
